openPR Logo
Press release

High Awareness in Female Population Regarding Hormonal Disorders Drives the Prescription Hormonal Drugs in Gynecology Market

05-17-2017 05:19 PM CET | Health & Medicine

Press release from: TMR - Research Reports

High Awareness in Female Population Regarding Hormonal

Global Prescription Hormonal Drugs Market in Gynecology: Description

Hormonal imbalance in women is caused due to abnormalities in the secretion of estrogen, progesterone and as well as androgens. A wide array of symptoms might be experienced by patients depending on the type of abnormality such as hot flushes, depression, vaginal dryness, excessive hair growth and abnormal vaginal bleeding. Environmental and genetic factors have an influence on women's fertility through their effect on hormonal function. Similarly, dysfunction of the HPO (hypothalamic-pituitary-ovarian) axis and/or other endocrine systems may cause infertility and other gynecological disorders. The correct clinical decision for treating these diseases can be made on pathogenetic basis.

Browse to unlock the hidden opportunities in Prescription Hormonal Drugs in Gynecology Market: http://www.transparencymarketresearch.com/prescription-hormonal-drugs-gynecology-market.html

Global Prescription Hormonal Drugs Market in Gynecology: Disease Overview

Disturbances related to the menstrual cycle lead to various syndromes such as polycystic ovary syndrome (PCOS), amenorrhea and premenstrual syndrome (PMS). Of all the above, PCOS is a common hormonal disorder seen among women that in the reproductive age. PCOS is a condition in which appearance of the ovaries in most, but not all women, is enlarged and features a number of tiny cysts located along the outer edge of each ovary. PCOS symptoms are observed in nearly 5% to 10% of women who are in their reproductive age (typically between 12 to 45 years).

PCOS is perceived to be among the leading causes of female sub-fertility. It is also among the most frequently reported endocrine problems in women in the reproductive age. Amenorrhea is a clinical condition wherein menstrual periods do not occur. Besides phases such as childhood, breastfeeding, pregnancy, and menopause, the absence of periods may point toward a problem in the female reproductive system. However, hormonal disruption is also a common cause for the absence of menstrual periods. Similarly, PMS is a medical condition that affects many women with childbearing age and causes variety of physical and psychological symptoms that occur just before menstrual cycle.

The prevalence of hormonal imbalance rate in women is high as the World Health Organization (WHO) estimates that PCOS affected 116 million women worldwide as of 2010 i.e. nearly 3.4% of the global female population. While in case of PMS, according to World Health Organization (WHO), in 2010, 199 million women had premenstrual syndrome i.e. nearly 5.8% of the global female population.

Global Prescription Hormonal Drugs Market in Gynecology: Drivers and Restraints

The major drivers of the hormonal drugs in gynecology market includes high awareness in female population regarding hormonal disorders, continuous research and development activities in the field of women healthcare and various government and organizational programs to educate women about the symptoms, precautions and treatments. The market for hormonal drugs in gynecology can be segmented on the basis of different drugs available in the market, different disease conditions and geography. Various drugs available for the treatment of hormonal disorders includes Depo-Provera, Prometrium, Provera, Alesse, Apri, Desogen, Junel Fe 1/20, Kariva, Loestrin Fe1/20, Vestura and others. Geographic segment of prescription hormonal drugs in gynecology market can be categorized into following regions: North America, Europe, Asia-Pacific and Rest of the World.

Brisdelle (low-dose paroxetine mesylate) product of Noven Pharmaceutical received approval in July 2013 against treatment of menopause condition. Brisdelle is a low-dose formulation of paroxetine mesylate, a selective serotonin reuptake inhibitor. Similarly, the new entity AZD4901 (Oral) is currently under phase II clinical trial for treatment of PCOS and this study is sponsored by Astra Zeneca. It is an interventional type of study including 56 as the target sample size.

Get accurate market forecast and analysis on Prescription Hormonal Drugs in Gynecology Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12563

The major players of prescription hormonal drugs in gynecology market includes Novartis AG, Pfizer, Inc., Berlex Laboratories, Inc., Ferring Pharmaceuticals, S.A., Duramed Pharmaceuticals, Inc. Xanodyne Pharmaceuticals, Inc., Bayer AG and others.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release High Awareness in Female Population Regarding Hormonal Disorders Drives the Prescription Hormonal Drugs in Gynecology Market here

News-ID: 540245 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Hormonal

Hormonal Contraceptives Market Size, Share | Hormonal Contraceptives Industry Fu …
Global Hormonal Contraceptives Market Report provides a detailed industry overview along with the analysis of Cost Structure, Supply Chain, Development Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels. Global Hormonal Contraceptives Market research report provides a point-by-pointIn-Depth analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations,
Hormonal Implants Market Outlook: Big Expectations to Watch For
Advance Market Analytics released a new market study on Global Hormonal Implants Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides
Hormonal Replacement Therapeutics - Pipeline Analysis 2018 | Novo Nordisk
Hormonal replacement therapy is a type of treatment wherein patients receive a course of hormones in order to get relieve from the menopause related problems. The therapy involves administration of synthetic estrogen and progesterone to overcome decreasing hormone level of women. Download the sample report @ https://www.pharmaproff.com/request-sample/1136 The most common signs and symptoms observed in patients with decreased hormone level are irregular menstrual cycles, and psychological symptoms (mood swings, anxiety, and
Global Hormonal Therapy Industry Market Analysis & Forecast 2018-2023
Global Hormonal Therapy Industry Market is divided into treatment type, dispersion channel, and application. Based on the treatment type, the worldwide market is isolated into estrogen substitution treatment, thyroid hormone substitution, and development hormone substitution. The thyroid hormone substitution portion is further sub-fragmented into tablets, infusions, and cases. Get sample copy of report: https://www.marketdensity.com/contact?ref=Sample&reportid=4477 Table of Contents Chapter 1 Hormonal Therapy Market Overview 1.1 Product Overview and Scope of Hormonal Therapy 1.2 Hormonal
Global Hormonal Contraception Market Research Report 2016
2016 Global Hormonal Contraception Industry Report is a professional and in-depth research report on the world’s major regional market conditions of the Hormonal Contraception industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China). The report firstly introduced the Hormonal Contraception basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and
Awareness in female for hormonal disorders is drives the Prescription Hormonal D …
Global Prescription Hormonal Drugs Market in Gynecology: Description Hormonal imbalance in women is caused due to abnormalities in the secretion of estrogen, progesterone and as well as androgens. A wide array of symptoms might be experienced by patients depending on the type of abnormality such as hot flushes, depression, vaginal dryness, excessive hair growth and abnormal vaginal bleeding. Environmental and genetic factors have an influence on women's fertility through their effect